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ARTICLE OPEN
Superhydrophobic lab-on-chip measures secretome
protonation state and provides a personalized risk assessment
of sporadic tumour
N. Malara 1, F. Gentile2, N. Coppedè 3, M. L. Coluccio 1, P. Candeloro1, G. Perozziello1, L. Ferrara4, M. Giannetto5, M. Careri5,
A. Castellini3, C. Mignogna 6, I. Presta6, C. K. Pirrone6, D. Maisano6, A. Donato6, G. Donato6, M. Greco6, D. Scumaci1, G. Cuda 1,
F. Casale6, E. Ferraro7, S. Bonacci6, V. Trunzo6, V. Mollace6, V. Onesto 1, R. Majewska8, F. Amato1, M. Renne9, N. Innaro9, G. Sena 9,
R. Sacco9, F. Givigliano9, C. Voci9, G. Volpentesta9, G. Guzzi9, A. Lavano9, E. Scali6, U. Bottoni6 and E. Di Fabrizio10
Secretome of primary cultures is an accessible source of biological markers compared to more complex and less decipherable
mixtures such as serum or plasma. The protonation state (PS) of secretome reflects the metabolism of cells and can be used for
cancer early detection. Here, we demonstrate a superhydrophobic organic electrochemical device that measures PS in a drop of
secretome derived from liquid biopsies. Using data from the sensor and principal component analysis (PCA), we developed
algorithms able to efficiently discriminate tumour patients from non-tumour patients. We then validated the results using mass
spectrometry and biochemical analysis of samples. For the 36 patients across three independent cohorts, the method identified
tumour patients with high sensitivity and identification as high as 100% (no false positives) with declared subjects at-risk, for
sporadic cancer onset, by intermediate values of PS. This assay could impact on cancer risk management, individual’s diagnosis
and/or help clarify risk in healthy populations.
npj Precision Oncology            (2018) 2:26 ; doi:10.1038/s41698-018-0069-7
INTRODUCTION
Cancer is the leading cause of deaths worldwide, it entails
immense human suffering and very high direct and indirect costs
for the health care.1 The mechanisms of cancer genesis and
development have been heavily investigated. Discovering effec-
tive techniques of detection for cancer may improve cancer
prevention, transform cancer treatment and may result in longer
life expectancy and improved lifestyle for the patient. In medical
diagnosis, moderate sensitivity and inadequate precision impair
the use of conventional analytical techniques for the assessment
of cancer risk. Similarly, medicine functional imaging techniques
lack the spatial and temporal resolution necessary to detect a
cancer at the early, non-reversible molecular stages of its
development. On the other hand, the large variety of cancer
types and the different declinations that cancer takes in individual
patients are the main cause of the failure of advanced
nanomedicine formulations.2 Despite recent advances in medical
diagnosis, tissue biopsy remains the gold standard for cancer
detection and diagnosis. In opposition to classical biopsy, liquid
biopsy may respond to the need for a personalized, noninvasive,
efficient cancer diagnosis. Liquid biopsy consists in the detection
of circulating DNA and/or tumour cells (CTCs) from peripheral
blood.3 Circulating biomarkers are highly specific but extremely
rare and diluted. Devices and assays have been developed for the
detection of cancers,4 the analysis and monitoring of cancer
progression,5 for the identification of relevant personalized
pharmacological targets.6 Nevertheless, no current approach is
competitive with clinical diagnosis.
Here, we demonstrate a superhydrophobic, organic electro-
chemical device that measures the protonation state of secretome
derived from liquid biopsy and associates it to cancer formation
and progression.The protonation state is a condition resulting in
the balance between protonation and deprotonation reactions
concerning the set of titratable groups of the protein that are not
involved in the structural peptide bonds. The device uses a
conductive polymer that is sensitive to the ionic strength of a
solution. Sensor surface is patterned at the micro- and nano-
scales. Microscale modification of the device enables super-
hydrophobic effects. Nanoscale modification of the device
improves time and spatial resolution of the sensor. The combina-
tion of the two spatial scales enhances sensitivity, enables
specificity and allows analyte detection at very low concentration
levels. The device combines various functions: (i) amplifies
differences between species, due to its non-wetting behaviour,
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through convective Marangoni flows in a superhydrophobic drop;
(ii) measures different ion currents associated to certain ionic
species in the secretome, through a conductive polymer coating.
Thus, specific species can be clustered on the basis of their
physical characteristics.
The secretome contains all products of the cell and reflects its
metabolism.7 The protonation state of the secretome is an
indicator of the solution conductivity state of proteins and cell
growth,8–10 therefore, it can be associated to abnormal cell
division, abnormal cell proliferation and invasion and cancer
progression.
Analyzing secretome derived from the expansion of non-
haematological cells11,12 extracted from cohorts of healthy, non-
healthy and patients suspected of cancer, the device was able to
cluster the different samples and to identify tumour and non-
tumour conditions, as well as the transition stage between the two
conditions, with high-sensitivity identification accuracy of 100%.
RESULTS
The surface-enhanced organic electrochemical transistors
(SeOECT)
Measurements of the protonation state were performed using a
surface-enhanced organic electrochemical transistor (SeOECT)
device. The device uses a conductive PEDOT:PSS polymer which
is sensitive to the ionic strength of the electrolyte. Nanoscale
modification of the device enables the detection of multiple
analytes at very low concentration levels. SeOECTs are a third
generation of organic thin-film transistors, in which the electrolyte
medium is an active part of the device gating. The selective
surface of 3D micro and nanostructured device, enhances the
properties of an electrochemically active conductive polymer
SeOECT. At the microscale (i), the arrays of superhydrophobic
micropillars enable manipulation and control of biological fluids
(Fig. 1a), whereas at the nanoscale (ii), five pillars, modified to
incorporate nano-electrodes (Fig. 1b, c), perform time-resolved
and space-resolved analysis of the solution.13,14 Each of these
electrodes is independently controlled and measures ionic
currents (Fig. 1c) that are directly proportional to the charge
and to the diffusion coefficient and inversely proportional to the
size of the molecules transported in the electrolyte.15 Mathema-
tical models can correlate the output of SeOECTs to the physical
characteristics of analyzed species in solutions.15,16 SEM micro-
graphs of the device show uniformity, reproducibility and verify
the fabrication process capability to attain extreme control over
shape and size of the micropillars over large areas (Fig. 1e). Pillars
are distributed on the substrate to form a non-periodic lattice, in
which their relative separation gradually changes from a
minimum, at the centre, to a maximum value at the border of
the pattern. The non-periodic design induces a nonuniform
surface energy density which generates in turn a system of radial
forces that recalls the drop to the centre of the lattice17 for sample
self-positioning. SEM micrographs in Fig. 1f show the system of
nano-electrodes on the pillars where nano-gold contacts with sub-
micron reciprocal distance generate enhanced and localized
electric fields. In the present configuration, the electrodes S1–S5
are placed symmetrically with respect to the centre of the device:
thus, the electrode/sensor S3 is at the centre of the chip,
electrodes/sensors S1, S5 are positioned at the extreme periphery
of the pattern or pillars and electrodes/sensors S2, S4 lie at an
intermediate position between S3 and S1, S5 (Fig. 1c). Convenient
post-processing of the chip assures super-hydrophobicity with
contact angles larger than 165° (Fig. 1d). An image of the device
correctly connected to an external probing station for data
acquisition and analysis is reported in Fig. 1g.
Measuring the protonation state of the secretome by the SeOECT
The secretome is subjected to specific changes in response to
fluctuations in physiological states or pathological conditions of
individual cells, corresponding to its immediate extracellular
volume. In a normal physiological context, the liquid phase of
the extracellular volume is characterized by ionic charge content
that depends on the PS of the total molecular solute. Perturba-
tions of this ionic charge perturb the PS with changes on electron
spin resonance (ESR) signal edited by protonation.8 Since the PS
depends on the rate of external molecular orbital resonance,
consequently, it is strictly linked to the available protonated
titratable residues. In 1965, Szent-Gyorgyi drew attention for the
first time to the ubiquitous glyoxalase/methylglyoxale enzyme
catabolic system that breaks down the 2-oxoaldehyde, a by-
product of glycolysis (Supporting figure S1a) and an indirect
regulator of both ‘conductivity state of proteins’ and of cell
growth.9,10 As Supporting figure S1a shows, the cellular metabo-
lism influences the state of intracellular molecular protonation
through the balance of glyoxalase/methylglyoxale. The changes in
the rate of glycolysis are the first perturbation reflecting changes
in cell division or cancer proliferation. The prevalent glucose
metabolism in the cancer cells, influencing 2-oxoaldehyde’s
catabolism, induces severe modification of their protonation state
with respect to normal cells.
We used the SeOECT device to analyze the secretome, made by
cultures of non-haematological cells isolated by liquid biopsy, of
control and cancer patients samples (clinical characteristics were
detailed in Data files S1 and S2) in a first cohort of 19 cases (signed
with * in Data files S1 and S2). Upon the application of an external
voltage at the gate (see Methods), the device measures the ionic
activity of charged species in the drop, due to the de-doping
effect of positive ions on the conductive polymer. The interaction
between positive ions and a conductive polymer results in a
current Ids proportional to the concentration of ions in the
medium. The process is completely reversible, since no irreversible
reaction, changing the composition of the solution takes place.
The output measurement is a function of time, as reported in Fig.
1c, where the ionic current gradually changes on time, from an
initial to a final current value, for a fixed voltage. We define
modulation m, the difference between the final and the initial
values of current, whereas the time constant τ of the device, as the
time necessary to reach 90% of its final stable signal. In Fig. 2, the
modulation for every measured sample is reported as a function of
the characteristic time constant for different values of external
voltage ranging from V1= 0 V to V5= 1 V and for different
measured points (i.e. electrode positions S1–S5) on the chip.
Assuming that the behaviour of the SeOECT can be described by
only two parameters, i.e. modulation m and time constant τ, each
point of the diagram is the state of the system at a specific
voltage, similarly to a graphical representation in the phase space
of a dynamical system. In the diagrams, white labels represent
control subjects (without cancer), black labels represent patients
(with cancer) and light-grey labels represent an intermediate
category (suspected with cancer). The control samples are
grouped into healthy and non-healthy subjects affected by
chronic inflammatory conditions. We observe that, for increasing
values of external voltage V, control samples gradually shift
towards the left-upper region of the plane (large modulation m
and low time constant τ), whereas, on the opposite region, patient
samples gradually shift towards the right-lower region of the
plane (low modulation m and large time constant τ). This trend is
even more pronounced for electrode S positioned at the periphery
of the device. For certain combinations of voltage V and sensor
position S, patient and control samples clearly cluster into
separate groups. In addition, to confirm the trend, we analyzed
a third cohort of nine subjects, four healthy and five affected by
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chronic inflammatory conditions signed with ** in Data file S1 and
reported in Supporting Information 2.
SeOECT operates sample clustering and classification
Qualitative analysis of Fig. 2 suggests that the device response and
sample separation is optimized for sensors positioned at the
periphery of the device where Marangoni convective flows are
maximized, in agreement with previously reported studies,14,18
and for high values of voltage Vg, i.e. an externally applied driving
force. We focused the analysis on sensor S5. The bar chart in Fig. 3
reports, for different values of voltage Vg= 0.2–1 V, the modula-
tion (b) and time constant (c) values of control and patient
samples, extracted from the scatter plot reported in Fig. 2. It is
noticeable that, with the exception of the first coordinate V1= 0.2,
(i) modulation is higher and (ii) time constant is lower in control
samples, compared to patient samples. In control samples, m
varies from 0.521 for Vg= 0.2 V to 0.606 for Vg= 1 V. Conversely,
in patient samples, m varies from 0.418 to 0.293 over the same
voltage range. As for time constant τ, in control samples and in the
same voltage range, the system moves from τ = 1.460 s to τ =
3.215 s and then reaches the steady state, in comparison with
patient samples where the signal reaches its final value τ = 4.257 s
for Vg= 0.2 V and τ = 5.329 s for Vg= 1 V. These differences are
statistically significant for all considered voltages (p < 0.05, Fig. 3a,
b). Since high m and low τ are indicative of fast-response systems,
these data suggest that the products released by control cells in
the secretome were more protonated than the products released
by cancer cells. A condition of high PS (secretome) generated a
final solution characterized by a higher ionic density or a more
electrically active secretome, with respect to patient cells. A lower
PS and a lower conductivity characterized the species secreted by
cancer cells.
Figure 3d represents the scatter plot in m–τ diagram for
samples with Vg= 1 V and electrode number S5, where differ-
ences between groups are maximized. The plot shows as the
samples are correctly classified into groups, on the basis of a priori
knowledge of their original populations belonging. Differently,
unlabelled points are presented in Fig. 3e, where nonetheless the
set of measurements falls into well-defined clusters. A density-
based, unsupervised clustering19 of unlabelled data presented in
Fig. 3e was used to classify elements into categories on the basis
of their similarity. The algorithm, determined cluster centres on
the areas characterized by a density of points higher than their
neighbours and by a relatively large distance from points with
Fig. 1 Super-hydrophobic chip incorporates five gold electrodes in a line for site-selective measurements of a solution (a). Individual silicon
micropillars are modified to incorporate gold nano-electrodes, an intermediate layer of C4F8 and a superficial layer of the conductive PEDOT:
PSS polymer, bar in the inset is 5 μm (b). Sensors are positioned from the centre (S3) to the border (S1, S5) of the device; the output of each
sensor is a function of time I(t) that reaches a constant value in a characteristic time τ; the intensity of I is proportional to the externally applied
voltage V (c). Convenient post-processing of a sample enables super-hydrophobicity with contact angles as large as 165° (d). SEM micrographs
of the device magnified at small magnification factors (e). SEM micrograph of the device shows the gold nano-electrodes positioned on the
pillar surface for localized sensing (f). Due to super-hydrophobicity, biological solutions can be manipulated and connected to an external
gate during operation (g). The images were partially adapted from https://www.nature.com/articles/srep18992 14
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higher densities. Points were then coloured according to the
cluster of the assigned group (Fig. 3f). The algorithm identified
two principal clusters. Upon cluster classification, we found that, in
the initial control set of patient points, only one control and one
patient element were assigned to incorrect clusters with a
classification error e= 1/14 ~ 7%. The very low mismatch between
the original data sets and their unbiased classification into clusters
using the described clustering algorithm confirms that the SeOECT
device operates sample identification and tumour detection with
high accuracy, high sensitivity and specificity. Nevertheless, device
specificity can be improved even further using the device
response in combination with a convenient statistical and PCA
analysis of data.
PCA-guided analysis of data
The device measures ionic current transients at five different
positions on the substrate and five different values of voltage. The
output of the device is lumped into two variables, modulation m
and time constant τ. Even without considering external environ-
mental conditions, the number of potential combinatorial varia-
tions through which one can represent the response of the system
is 75!/(73! 2!)= 5550. It is nearly impossible to test all combina-
tions of voltage V, sensor position S and modulation and time
constant labels, to screen them for the best and more informative
representation of the response of the device. While this device
offers a wide investigation for improved diagnosis of cancer, at the
same time, it poses the problem of selecting the most
representative coordinates. In this context, statistical analysis
and principal component analysis of data can be used as a
preliminary reference for finding representative patterns in the
data and to optimize the sensor response.
The whole data set was subjected to Multifactorial ANalysis Of
VAriance (ANOVA) in order to individuate the experimental
variables significantly correlated to the sample, i.e. control (C) or
patient (P) cells, using the time constant τ and modulation m
outputs from the five sensors (Supporting Information 3). The
Fig. 2 Device response. The response of the sensor, in the analyses of a secretome made by cultures of non-haematological cells isolated by
liquid biopsy of control and cancer patients, is described by the sole two parameters modulation m and time constant τ. m–τ scatter plots
evaluated for different values of applied voltage V and sensor position S are descriptive of the physical characteristics of the system. Sample
separation is operated for high values of voltage and elevated sample numbers. In the diagrams, white label represents control subject (C,
without cancer), black label represents patients (P, with cancer) and light-grey label represents intermediate category (I, suspected with
cancer)
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classification factors for ANOVA were the applied potential at the
gate Vg and sample typology. Multifactor ANOVA was carried out
on τ outputs, evidencing a significant effect of both Vg and
sample variations. Graphical ANOVA from Bonferroni post hoc test
is reported in Fig. 4a. Figure 4b shows the interaction plot from
the ANOVA carried out on the τ outputs, evidencing a significant
discrimination between C and P samples for Vg values higher than
V4. Analogous multifactor ANOVA carried out on modulation
outputs m also evidenced a significant effect of both Vg and
sample variables. Graphical ANOVA from Bonferroni post hoc test
Fig. 3 Data analysis of a secretome made by cultures of non-haematological cells isolated by liquid biopsy of control and cancer patients. Bar
chart plots of modulation m (b) and time constant τ (c) at sensor S5 for all samples are reported as a function of V. (d) Scatter plot of each m–τ
pair is a point whose position varies depending on V. On varying V in the V1–V5 interval, m–τ doublets delineate a trajectory distinctive of
measured samples. Trajectories associated to different sample types, i.e. control, patients and intermediate samples, are not intersecting. m–τ
scatter plot of the whole data set acquired at V5–S5 is reported with (d) and without (e) identification labels. Data set into clusters (f), correctly
operates assignation of C and P samples into two different groups
Fig. 4 Data set of the secretome made by cultures of non-haematological cells isolated by liquid biopsy of control and cancer patients
measured through the device was subjected to ANOVA analysis. Graphical ANOVA from Bonferroni post hoc test shows control C dissimilar
from patients P samples with a 95% confidence interval and 5% significance level, for both time constant (a, b) modulation (c, d) measured
variables. Interaction plots carried out on time constant (b) modulation (d) outputs, showing significant discrimination between C and P
samples for values of potential at the gate V higher than V3. PCA analysis performed to reduce noise and extract from the whole data set
combinations of voltage and sensor number, V–S, in correspondence of which sample separation may be optimized (e)
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is reported in Fig. 4c. Figure 4d shows the interaction plot from the
ANOVA carried out on the modulation outputs, evidencing
significant discrimination between control and patient samples
observed for Vg values higher than V3. On the basis of these
findings, principal component analysis (Supporting Information 3)
was carried out for both modulation m and time constant τ,
including independent outputs from five sensors and excluding
from the data set the measurements performed at non-significant
values to reduce noise in the data-modelling procedure. Selection
of best PCA outputs led to the identification of optimal
combinations of electrode position and applied voltage (Fig. 4e)
that were not otherwise immediately identifiable through direct
visualization of data. In Fig. 5a–f, we report scatter plots of data
within six different frames of references (S1V4 m–S5V4m),
(S1V5m–S5V5m), (S4V3m–S5V5m), (S3V4τ–S1V4m), (S3V5τ–S1V4m) and
(S1V4m–S5V5m) extracted from the best PCA variables. At the side
of each scatter plot, we report unsupervised clustering of sample
data performed using the algorithms described in the precedent
section. For the considered configurations, all data points are
correctly categorized into patient and control groups with 0%
classification error and 100% identification, with the exception of
the configuration (S4V3m–S5V5m), where the matching between
the experiments and the prediction of the model has an efficiency
of nearly 93% (the clustering algorithm used was detailed in
Supporting Information 4). Similar results were obtained on
analyzing a third independent cohort of eight patients (signed
with *** in Data files S1 and S2), as described in a separate
Supporting Information 5.
Biochemical characterization of secretome and clinical transfer
To obtain a complete understanding of the composition of
molecular products released by cultivated cells into extracellular
space, we collected the medium conditioned for 2 weeks. In
particular, we used a protocol involved in the isolation of
circulating non-haematological cells from peripheral blood in
cancer patients previously reported,11,12 thus identifying a specific
density phase for CTCs in peripheral blood. The cells isolated from
this phase are then put to seeding, as previously describe-
d11,12,20in a specific culture medium and expanded for 14 days.
The short-time cultivation protocol was optimized during many
Fig. 5 Data clustering and sample identification. On the basis of PCA analysis, we selected the best combinations of voltage, sensor position,
modulation and time constant that optimize the response of the device and maximize separation of the sample of secretome made by
cultures of non-haematological cells isolated by liquid biopsy of control and cancer patients, between variables (a–f). For all considered
configurations, data were clustered into control and patient groups with a specificity up to 100% with the exception of configuration (c),
where matching the efficiency of classification is nearly 93%
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experiments, which allowed us to pinpoint the time required to
show up the proliferative capacity of the transformed cells and to
preserve their original phenotypes. In order to save the hetero-
geneous composition of the CTCs, our approach does not make
any selection of phenotypes during the initial phase. In fact,
we expect the circulating tumour progeny to be made of cancer
cells with an epithelial or mesenchymal or hybrid
epithelial–mesenchymal phenotypes. The same protocol was
applied in healthy and non-healthy patients to isolate circulating
non-haematological cells. The non-haematological cells expanded
in vitro were characterized for the expression of specific cancer
markers, as reported in Supplementary Information (Supporting
Figure S1b–g).
The principal constituents of BDC’ secretome (BDCS) were
proteins, 2.53 ± 0.18 mg/ml and 2.09 ± 0.91 mg/ml; DNA double
strands, 599 ± 34 ng/ml and 211 ± 50 ng/ml; RNA, 393 ± 95 ng/ml
Superhydrophobic lab-on-chip measures secretome protonation state. . .
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and 191 ± 36 ng/ml; DNA single strand, 298 ± 48 ng/ml and 81 ±
31 ng/ml measured, respectively, in patients and the control group
(Fig. 6a). The BDCS from patients was richer in any component
compared to control BDCS (p= 0.001) and its protein content
correlated with the grade (r= 0.6). We were intrigued by a
possible qualitative correlation between BDCS and the interstitial
fluid phase of tumours (TM). TM is a component of the internal
milieu of a solid tumour and the present proteomic technologies
validated it as a valuable source for specific tumour marker
candidates.21 TM was isolated directly from the fresh tumour
specimens, as described in Raso et al.22 A strong correlation (r=
0.9) between medium conditioned (MC) and TM in the same
patient (Fig. 6b) was found applying mass spectrometry (MS)
carried out under positive and negative ionization mode. In
addition, we compared MC and TM for pro-inflammatory cytokine
levels, including interleukin-1 (IL-1a, IL-1b and IL-1ra), IL-2, IL-4, IL-
8, IL-10, IL-16, IL-17, IL-17E, C5a, G-CSF, GM-CSF, MCP-1, MIF, ICAM-
1, GROα, IP10, SERPIN E1, RANTES and SDF-1 (Fig. 6c). The
correlation found for each patient ranged from r= 0.4 to r= 0.7.
We therefore compared the control group with the patient group
in terms of the total production of cytokines, evidencing a
significant difference between the two groups (p ≤ 0.005) (Fig. 6d).
To confirm the difference on the device data in terms of
secretome protonation state (SPs), within MCs collected from the
two analyzed groups, an isoelectrofocusing assay was performed.
It was observed on different values of an isoelectric point between
the two clinical groups, as shown in Fig. 6e. Based on our first
hypothesis, we explored the relationship between metabolism
and SPs through the quantification of secretome glycation end
products. An increased level of methylglyoxal (MG) glycation end
products (MEGs), prevalently derived from the MG reaction with
proteins, was found in the patients’ secretome (Fig. 6f) (p < 0.05).
Expanded cells were analyzed in terms of cell cycle phase
distribution focusing on the S-phase referencing to their
proliferation rate (Supporting Information 1). The patients with S
phase > 50% were characterized by high levels of MEGs (p=
0.002). Immunofluorescence assay (Fig. 6h), using antibodies
against MGEs and p21 (CIP1) showed that the prevalence of
expanded CTCs with nuclear expression for p21 expression did not
display cytoplasmic accumulation of MGEs. These features were
not supported by a significant correlation with S-phase value.
Finally, Kaplan–Meier curves and an assessment of survival data
were performed. The patient with a secretome with high MGE
levels had a worse prognosis (Fig. 6h); therefore, no significant
difference in terms of disease-free survival was found.
Difference in antioxidant defence profile of the samples separated
by the SeOECT
To better establish the role of MGEs in the cancer pathogenesis,
we investigated the early-stage protein glycation and advanced-
stage protein glycation biomarkers, the nitrosation and oxidative
stress23 (Supporting Table S1) in MCs separated by SH-BioChip.
The early-stage protein glycation products23 are due to direct
interaction between glucose and the amino groups of lysine
residue side chains, as well as N-terminal amino acid residues,
leading to a Schiff’s base adducts, commonly defined as fructosyl-
lisine residues (FL). These early-stage glycation adducts are
relatively rapidly reversed. The advanced-stage protein glycation
Fig. 6 Characterization of secretome in conditioned medium by blood-derived cultures 14 days aged. a Spectrophotometric quantification in
the secretome of proteins, DNA double strands, RNA and DNA single strand. b Correlation between in vitro (conditioned medium (MC)), and
in vivo tumour microenvironment (interstitial fluid phase of tumours (TM)) in the same patient, **r= 0.8; ***r= 0.9. c of the MS fragment ions
by mass spectrometry. c Heatmap shows cytokines in a conditioned medium: row represents a patient and column a cytokine. Color intensity
represents the levels of cytokine. Each cytokine in the data matrix is obtained through averaging two values quantified on cytokine-array
membranes. The error bars are the sum of standard deviations between two values of pixel intensity for each of the patients. d Plots by
repeated measures ANOVA show distributional levels of the cytokines in control and patients’ groups (p < 0.05). e Isoelectrofocusing assay on
conditioned medium shows the pH value at which the net surface charge switches its sign. f Comparative levels of methylglyoxal (MG)
glycation end products (MEGs) in MC assessed through immunoblotting. g Intracellular localization by immunofluorescence with antibodies
against MGEs (green) and p21 (red) in breast cancer cases (reported in Data file S2). Scale bars 10 μm. h Kaplan–Meier curves show a worst
prognosis for patients with secretome content high levels of MGEs
Fig. 7 Schematic drawing of samples’ trace and correspondent MS profiles. The trajectory moves from control (grey) to patients (black).
Intermediated samples (green) are localized at approximately the halfway point. The right-hand image shows mass spectrometry results
performed on MC samples from control and patients groups. High-resolution single-ion monitoring MS, shows the pseudo molecular ion
signal of G-H1, MG-H1, methionine and CEL, corresponding to, respectively, ([M+H]+), ([M−H]−), ([M+H]+) and ([M+H]+)
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products are stable end-stage adducts formed by the interaction
between endogenous a-oxoaldehyde metabolites, methylglyoxal
and a minor contributor glyoxal with different site-specific
distributions on proteins (Supporting Figure S1a).23 A major
advanced-stage glycation product found in human is the
methylglyoxal-derived hydroimidazolone, N-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine (MG-H1)24. A further minor
methylglyoxal-derived product is the stable N-(1-carboxyethyl)
lysine (CEL) which is mainly formed in the non-enzymatic reaction
between methylglyoxal and lysine. Glyoxal advanced-stage
glycation products are represented by (N2)-G-H1 (G-H1), N-(1-
carboxymethyl) lysine (CML) and (H8)-GOLD (GOLD). The markers
of oxidative stress MetSO and dityrosine with the marker of
nitrosative stress, 3-nitrotyrosine, were determined24 by triple-
quadrupole MS. In the control group, clustered in the upper-left
region of the chip platform, the correspondent MCs assayed by
MS were prevalently (75%) characterized by total absence of early
and advanced-stage protein glycation products and nitrosation
and oxidative stress biomarkers. Moreover, 20% of samples were
characterized by a unique type of advanced-stage protein
glycation glyoxal derived (GH1) (Fig. 7). In the case of MCs from
patients group, clustered at the bottom-right part of the SH-
BioChip plane, 60% of samples were MG-H1 and CEL positive
where 20% presented also FL, whereas the remaining 40% was
positive for G-H1 and GOLD. Only the group of patient samples
displayed a compromised antioxidant defence evidenced by
relative peaks for dityrosine and 3-nitrotyrosine.
SeOECT reveals personalized risk of sporadic cancer
Two samples from the control group showed an intermediate
behaviour on the chip. Within the range of the considered voltage
length, intermediate samples revealed modulation and time
constant values lying approximately halfway between control
and patients samples (Fig. 3a–b). Intermediate samples were
statistically different from both, the control and patients’ samples,
with p < 0.10 for modulation and p < 0.05 for time constant. A
curve or a trajectory that describes the evolution of the system as
a function of voltage can be obtained by reporting the centre of
mass of samples in the same τ–m diagram (Fig. 3c) for different
values of voltage. This graphical representation of the system may
unmask the otherwise hidden data patterns and highlight
differences between different data sets. For the present config-
uration, similar non-overlapping diverse trajectories confirmed
that the analyzed samples originated from different populations
representing specific clinical cases. In a more sophisticated
evolution of the technique, trajectories in a phase-space diagram
obtained by using the SeOECT may reveal variations in the normal
course of the physiological/pathological performance of the
subjects. The peculiar behaviour of the intermediate samples
subgroup suggested an intermediate value of PS with respect to
the two major clinical groups analyzed. Intermediate subjects
could be identified as 'subclinical entities' in which protein
biomarker profile characterized by peaks for MGH-1, CEL and
MetSO oxidative stress biomarker (Fig. 7), as well as the position
on the SeOECT, revealed a profile for reactive dicarbonyl
detoxification and antioxidant defence, under siege, but not
collapsed. To date, only one of these two subjects, after 80 months,
was diagnosed with melanoma in situ (Clarke level 1).
DISCUSSION
The device used in this study is an electrochemical transistor,
which allows for direct current measurement that is proportional
to the ionic strength of the solution. Micro and nanoscale device
architecture introduces additional degrees of freedom in the
system, enabling sample manipulation, through Marangoni
convective flows, and time- and space-resolved sample analysis
at the nanoscale. The intensity of Marangoni flows in a point of
the device depends on (i) the curvature of the drop, (ii) the
distance of that point from the centre of the drop and (iii) the
gradient of temperature from the substrate to the solution in the
drop. However, it is to be noted that (i) the curvature of a drop is
the inverse of its radius, φ= 1/R; thus the smaller the drop, the
higher the Marangoni effects. Nevertheless, drops with a radius
smaller than ~1mm (that corresponds to a volume V ~ 4 μl)
cannot be easily spotted on the device and can easily be
manipulated or controlled. Moreover, they may contain few target
molecules that hamper the readout of the device. Thus, the
curvature of a drop may be limited by the implementation of the
device and at the—current state of the art—the use of
exceedingly small drops (i.e. nano-drops), can be impractical.
(ii) If the curvature (radius) of the drop is fixed, the maximum
distance at which a sensor can be positioned is determined by the
angle of contact ϑ of the drop with the superhydrophobic device.
The radius r of the circumference at the solid–liquid interface is r
= R (4/ξ)1/3 sinϑ, with ξ= (1− cosϑ)2 (2+ cosϑ), that yields r
~300 μm for ϑ= 160° and R= 1mm. Thus, ~300 μm is the
maximum distance between the centre and the border of the
device in standard operation conditions. Notice that r is limited by
R. If one wants to maintain R low, in order to increase the
curvature of the drop, then r will be necessarily small, with limited
leverage of Marangoni flows. Consequently, acting on the
geometrical constraints of the device does not appear to be a
promising strategy for improving efficiency.
(iii) The intensity of thermo-capillary-driven Marangoni flow in a
small droplet depends on the difference between the temperature
inside the drop and the temperature on the substrate −ΔT= T−
Ts. While small ΔT normally results from the differences of heat
conductance between the solid substrate and the liquid phase in
the drop, additional ΔT can increase even further the intensity of
Marangoni flow, maximizing the response of the device.
Additional ΔT can be obtained by placing the device on a hot
plate with accurate control of the temperature at the surface of
the plate.
Thus, while Marangoni flows can be in theory maximized using
sensors positioned far away from the centre of the device in small
drops, in practice, the most effective strategy for increasing the
response of the device is to use controlled temperature gradients
at the device–solution interface.
On the other hand, the convenience of using multiple sensors in
the device is that
(a) They increase the statistical significance of the analysis;
(b) They generate large data sets that can be analyzed using
PCA or other statistical analysis techniques for finding the
best combinations of variables that minimize uncertainty
and maximize the response of the device;
(c) They enable to resolve complex mixtures where the number
of unknown species is equal to the number of sensors.
The combination of different length scales allows signal
amplification, increases resolution and improves sensitivity of
the device. The device is thus capable of registering otherwise
undetectable changes in the protonation state of the secretome
that, in turn, are clues of cancer genesis.
The surface-enhanced organic electrochemical transistor
(SeOECT) allowed the identification of samples based on the
protonation state of their secretome.
The combination of two variables, m and τ, reduces uncertainty
and the likelihood of incorrect assignments, thus improving
analytical reliability. The different trajectories that in a phase-space
diagram can be clearly associated to healthy, non-healthy and
precancerous samples, highlight the relevance of the protonation
state of the secretome in evaluating the cancer state.
The results were confirmed by independent phenotypic and
biochemical analysis of 60 non-haematological cell cultures.
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Metrics measuring clinical differences between samples were used
to resolve groups and patient cases and assigned to correct
clusters with small classification errors. This is the result of an
initial selection of patients and control subjects that excluded
from the analysis possible interference cases (i.e. patients with
constitutional dysmetabolic glucose pathways). Thus, accurate
preselection of patients is relevant for the correct matching
between the prediction of a model with true clinical and biological
data.
Taken together, the results support the idea that the protona-
tion state of the secretome, which refers to the microenvironment
of circulating non-haematological cells, reflects intracellular
changes in the levels of methylglyoxal glycation end products,
which are relevant actors of the glycolitic pathway. This concept is
supported by findings on the characteristics of the secretome
made from expanded non-haematological cells isolated from the
liquid biopsy of control subjects and patients. To clear how those
secretomes are more or less 'electrically active', we used two
parameters, i.e. m and τ. Since high m and small τ are indicative of
fast-response systems, these data suggest that the products
released by control cells in the secretome were protonated more
than the products released by cancer cells. Conditions of high PS
of the solutes dispersed in the secretome generate a final solution
characterized by a higher ionic density or, in other words, higher
electrical activity and conductivity that are relieved by the
'controlled perturbation' performed by the SeOECHT. The
SeOECHT highlighted a lower PS and a lower conductivity
characterizing the protein species secreted by cancer cells. These
data suggest that the secretome made from expanded non-
haematological cells isolated from the liquid biopsy of healthy
subjects presents a faster kinetic diffusion than the secretome of
patient cells. These physical conditions are even a biological
explanation of the cancer process. The metabolic switch occurring
within the cancer cells consists in an increase of the cytosolic
glycolytic pathway that avoided the mitochondrial stations. This
behaviour is responsible for a cytoplasmic increase of reactive
aldehyde’s concentration. These reactive molecules are able to
interact with titratable amino acids exposed by the building block
of all proteins. The set of titratable groups of the protein is not
involved in the structural peptide bond, thus being capable of
protonation and deprotonation. The amount of charged titratable
group of the protein affects the electrostatic properties of the
solution in which they are contained. The higher concentration of
the aldehydes (i.e. methylglyoxal, glyoxal) within the cytoplasmic
cancer cell favours the interaction with titratable side chains to
build final molecular complexes, i.e. the adducts. The adducts
have a density of electric charge higher in the internal part of the
molecule with respect to the surface and are characterized by
lower conductivity and lower electrical state rather than the native
protein, with an influence on the electrostatic properties of the
cytoplasm, and of the secretome, when released in the next
microenvironment.
In addition, the results showed in Fig. 6 demonstrate that the
secretome of circulating cancer cells could be considered a good
reference of the primary tumour interstitial fluid, further confirmed
by the strong correlation between the levels of methylglyoxal and
the data survival of cancer patients. In Fig. 7, we highlighted the
link between the metabolic switch occurred in the non-
haematological cells and the impact of this on the oxidative
defence, showing a 'gradient' in the levels of the glycation
products comparing the healthy with cancer patients, with an
inverse behaviour for the levels of the reduced forms of the
antioxidant molecules.
In cancer patients, the presence of circulating tumour cells in
the liquid biopsy and relative culture, conditioned the presence of
high levels of glycation products. The circulating cancer cells
represent the most specific biomarkers actually available and
detectable by liquid biopsy. The high specificity of this biomarker
is compromised by the low sensitivity of the current methodology
used to detect them. Cell-search, Veridex and other methods
using an immune-selective approach underestimate the CTC
quantification irrespective of the heterogeneity of this kind of
population. The present device is able to discriminate cancer and
healthy patients as a function of the presence of the CTCs revealed
through the physical characteristics of their metabolic product
released in the culture medium. The metabolic products became
here the reference for the presence of circulating cancer cells in
the correspondent culture. This approach overcomes the proble-
matic relative to the heterogeneity and the loss of antigen on the
cell surface that are in part responsible for the failure of the
methodology followed in the immune selection of these cancer
cells. The biosensor detects and characterizes the metabolic
species produced by specific biomarkers represented here by the
CTC and its secretome.
The case of intermediate values of PS measured with the device
deserves to be discussed even further. Samples with intermediate
values of PS identify a fuzzy phase in which the process of cell
transformation is started at a metabolic level but is not evident in
order to the classical indicators of cancer (cell atypia, genetic
alterations and clinical evidence). Thus, intermediate PS values
highlight an intra/extracellular condition ongoing to malignant
transformation (50% of the analyzed patient’s samples developed
cancer disease) characterized in Fig. 7 by a down level of the
antioxidant defence and by an up level of glycation products in
their secretome with respect to the healthy subjects.
In the field of preventive medicine, this study suggests the
exciting perspective that would allow to individuate healthy
subjects with high cancer risk and to submit them to a
personalized monitoring program supported by specific prescrip-
tions or lifestyle guidelines.
Further studies are needed to understand how the pathway
identified here can be used to design personalized medicine
intervention that may limit, hamper or possibly revert cancer
progression.
METHODS
All chemicals, unless mentioned otherwise, were of analytical grade and
were used as received. The complete list of chemicals and reagents used in
the study is reported in Supporting Table S2.
Experimental model and subjects details
Blood samples have been collected prospectively from patients at the
clinics of the Department of Clinical and Experimental Medicine and the
Department of Medical and Surgical Sciences, University 'Magna Græcia' of
Catanzaro, from July 2013 up to the present. The study named CHARACTEX
(CHARActerization of Circulating Tumor cells and EXpansion) was approved
by the local institutional reviewer board and conducted according to the
recommendations of the Declaration of Helsinki and its amendments. The
study approval number is 2013.34. Enrolled subjects provided written
informed consent and were given a patient information sheet detailing the
following aspects of the study. Peripheral blood samples (total volume of
5ml) were drawn from both controls (volunteer healthy subjects) and
untreated patients with a primary diagnosis of cancer, placed into tubes
containing EDTA as an anticoagulant. All subjects enrolled in this study,
had a ‘normal’ glucose level of 70–85mg/dl and family history without
cases of diabetes and/or neurodegenerative diseases. Subsequently, the
samples were processed following the procedure described previously by
Malara et al.20 Patient age, sex, diagnosis and clinical status are described
in Data files S1 and S2.
Liquid biopsy primary culture
To develop the culture, cells of interest were isolated by a working range,
as previously reported by Malara et al.11,12,20. After washing in phosphate-
buffered saline (PBS), the cells were recovered in a medium promoting
in vitro expansion for 14 days (short-term cultivation). The medium
composition was reported in Malara et al.11,12,20
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In brief, peripheral blood sample was collected and submitted to a
gradient procedure. This phase is useful to reduce the haematological cells
contamination. The phase taken during this procedure was enriched for
non-haematological cells, as previously reported in cancer cases.11,12,20 The
isolated solution of cells during the gradient procedure is washed and
seeded in a culture plate with the addition of a specific culture
medium.11,12,20 The cultures were performed for 14 days of cultivation.
This timing was assessed to permit the transformed cells to become visible
through their self-altered proliferation feature. The same protocol applied
in healthy subjects and subjects with inflammatory disease highlighted the
presence of non-haematological cells, prevalently endothelial cells able to
survive in vitro and with a limited expansion power supported by a lower
S-phase.
Secretome collection and characterization
The cell cultures were monitored at 48-h intervals and each time, 10% of
total volume of the culture medium was collected and replaced with fresh
medium. The 10% of collected medium was placed in a cuvette and stored
at 4 °C. After a 2-week incubation, the culture was harvested and the
medium was separated from the cellular elements by centrifugation at
1870 rpm for 15min. The supernatant was added to the previous collected
medium, filtered and stored at −80 °C. The pellet formed was collected
and used for successive characterizations.
Cytometry
Cultivated cells were analyzed with a panel of antibodies designed to
identify different populations of naive haematological and non-
haematological cells (the list of antibodies used in panel and control
tubes is described in Supporting Table S2). The panel included markers
non-specific to cancer cells, which, however, provided relevant information
in the multipanel context. Cells were fixed and permeabilized using the BD
IntraSure kit. All antibodies were titrated to obtain optimal dilution for the
present experimental setting. Instrument performances and data reprodu-
cibility were checked using Cytometer Setup & Tracking Module (BD) and
further validated through acquisition of Rainbow Beads (BD). Compensa-
tions were calculated using CompBeads (BD) and single-stained fluor-
escent cells for DNA dyes (Syto16 and 7ADD). Flow cytometry was
performed with a FACS ARIA III (Becton Dickinson) analyzed with FACSDiva
v. 6.1.3, and FACSuite v1.05 (BD) software. Cell cycle phases distribution
was performed using the Becton Dickinson kit: CycleTEST plus DNA
reagent Kit, data acquisition using FACS Canto II (Becton Dickinson) and
the analysis was performed with ModFit LT software (http://modfit-lt.
software.informer.com/4.0/)
Immunofluorescence
For cellular immunofluorescent staining, cells on slides were fixed with 4%
paraformaldehyde for 15min at 22 °C. The slides were washed three times
with phosphate-buffered saline (PBS) and then blocked with PBS contain-
ing 0.2% Triton X-100 and 10% bovine serum albumin for 1 h.
Subsequently, the cells were then incubated with primary antibody
(1:1000) for 16 h at 4 °C and washed three times with PBS. Next, the cells
were incubated with Alexa Fluor 633—or Alexa 488-conjugated secondary
antibody for 3 h at 22 °C and viewed using a laser confocal microscope
(Nikon TI-E). The TI-E microscope software was used to morphometrically
analyze the fluorescence intensity.
Protein/DNA/RNA assessment
The secretome aliquots were used to assess the protein/DNA/RNA content.
Measurements were performed at 280/260-nm wavelength using Nano-
Drop™ (Thermo Scientific) which allows micro-volume (1 µl) sample
measurements and at the same time by a spectrophotometer (Gene
Quant pro, GE Healthcare. Quartz cell 5-mm pathlength). Each time, three
assays were performed on the same sample set for comparison.
Cytokines and growth factors array
Cytokine and growth factor levels were evaluated simultaneously using the
'Cytokine & Growth Factors Array (CTK)' kit, the Evidence Investigator
biochip analyzer (Randox Labs, UK) and by the Proteome Profiler kit (R&D
system).
Isoelectric focusing and immunoblotting
Total protein content of the extracts was determined using the Bradford
Protein Assay (Bio-Rad) with human serum albumin (Sigma Aldrich) as
standards, according to the manufacturer’s instructions. Fifty micrograms
of each proteins extract were diluted with Laemmli buffer and incubated at
100 °C for 5 min. Subsequently, all samples were loaded onto a 12% SDS-
polyacrylamide gel and electrophoresed at 50 V. After electrophoretic
separation, SDS gel was electrotransferred to a nitrocellulose membrane by
Trans-Blot Turbo system (Bio-Rad) protein transfer system. Membranes
were incubated using the primary antibody direct against methylglyoxal-
modified proteins, lipids and nucleic acid. The detection of primary
antibody was done with anti-mouse horseradish peroxidase-conjugated
secondary antibodies (Cell Signaling) for mouse primary antibody. Blots
were developed using the SuperSignal West Femto ECL substrate (Pierce,
EuroClone). Fully automated densitometric software Alliance 2.7 1D
(UVITEC, Eppendorf, Milan, Italy) was used to determine the percent
distribution of blotted proteins and the image acquisition. Proteins extracts
were mixed and resuspended into isoelectrofocusing (IEF) sample buffer
containing 8M urea, 4% CHAPS, 0.1 M DTT and 0.8% IPG buffer, pH 3–10
NL. IEF was performed using a nonlinear precast IPG strip (pH 3–10 NL; 24-
cm long, GE Healthcare). The first dimension separation was carried out on
an IPGphor unit (GE Healthcare), which to a total of 70 kVh was reached.25
After IEF separation, the IPG strip was stained with silver-staining
procedure.
Mass spectrometry analyses
A Thermo Scientific Q-ExactiveTM (Rodano, MI, Italy) mass spectrometer
was operated using electrospray with both negative and positive polarities
at 140000 resolving power and ACG target= 3e6, by SIM (single ion
monitoring) analysis. Source conditions were spray voltage 3.4 kV, sheath
gas: 30 arbitrary units, probe heater temperature: 280 °C; capillary
temperature: 350 °C; S-lens RF level: 50.
SeOECT chip fabrication
Surface-enhanced organic electrochemical transistors (SeOECT) were
fabricated using micro and nano fabrication techniques, as reported in
refs.17,26,27
SeOECT chip operation
Samples containing cell culture liquids were gently positioned upon the
active surface of the biosensor device in the form of drops of volume V <
10 μl. The electrical response of biosensors has been measured using a
two-channel source/measure precision unit (Agilent B2902A), controlled by
a homemade software. Biosensor measurements were acquired by
measuring the drain current Ids versus time under a constant drain
voltage Vds=−0.1 V, while varying the voltage at the gate Vgs between
0 V and a positive value that was gradually increased from 0 V to 1 V with a
step of 0.2 V, with a time interval of 120 s. Biosensor current response is
expressed as current modulation ΔI/Io= (I− Io)/Io, where I is the drain
current value measured for Vgs > 0 V and Io is the Ids value at Vgs= 0 V.
Statistical analysis
All data are reported as means ± standard deviation with the exception of
cytometric data that are reported as means ± standard error. A three-ways
analysis of variance (ANOVA) was used to explore the relationship among
marker expressions, clinical parameters and cancer characteristics. The
significance level was set at p < 0.05. Repeated measures analysis of
variance (ANOVA) was performed to assess the distributional levels of the
cytokines in control and patients’ groups (p < 0.05). Comparison between
patients and the control group was performed using Mann–Whitney and
Kolmogorov–Smirnov tests with a valid statistical significance of p < 0.05.
In order to rank the correlation and direction of linear relationships
between pairs of continuous variables such as cell characteristics and
secretome content across patients and controls, we used the Pearson
correlation coefficient. Sub-groups were compared using the T test (for
continuous variable) and chi-square test or Fisher test (for categorical
variables). Follow-up of the patients was defined as the number of months
from diagnosis until the first occurrence of loco regional or distant-
relapsing lesion or death if any of these occurred. Survival analysis has
been conducted using the Kaplan–Meier method, log-rank test. All
statistical analyses were performed using MedCalc for Windows, version
18 (MedCalc Software, MariaKerke, Belgium). The heatmap of cytokine
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levels in MC and TM was displayed in MathLab v.R2016 b. Each cytokine
level, assessed with a proteomic array kit (R&D system), represents the
average of the two values of pixel intensity quantified on spots of the
cytokine-array membranes with ImageJ software.
Cytometry data were analyzed using a multivariate mathematical
approach in order to identify several cellular patterns across the different
patients. For this purpose, 5000 cells representing grade I, grade II, grade III,
grade IV patients and healthy individuals (summing up to 25,000 cells)
were extracted from FACS data. For each cell, the scattering intensities of
ten fluorophores were recorded. A principal component analysis (PCA) was
applied to the whole fluorimetric data set.
Analysis of variance of biochip data
Modulation and time constant variables acquired for the entire population
of control (C), patients (P) and intermediate (I) samples (data set) were
subjected to Multifactorial ANalysis Of VAriance (ANOVA), in order to
individuate the experimental variables significantly correlated to the
sample label. ANOVA was performed using the Statgraphics Centurion XV
statistical software (Statpoint Technologies Inc., Warrenton, VA, USA). In the
ANOVA analysis, the modulation and time constant outputs from the five
sensors (pooled in this stage of data management) were considered.
Intermediate samples were intentionally excluded from the model
development to improve its predictive power. The classification factors
for ANOVA were the applied gate potential and sample typology.
Bonferroni post hoc test on time constant and modulation outputs was
carried out considering as significant the factors with p < 0.01. Two-way
ANOVA interaction plots of time constant outputs and modulation outputs
were realized according to the significance found in the test, reporting the
mean value and the Bonferroni confidence intervals (p= 0.01).
Principal component analysis of biochip data
On the basis of ANOVA results, PCA was carried out both for modulation
and time constant outputs, including independent outputs from the
different five sensors and excluding from the data set the measurements
performed at Vgate values non-significantly associated to the 'label' of the
samples, in order to avoid the introduction of 'noise' in the data-modelling
procedure. The entire statistical analysis is described in detail in Supporting
Information 2 and 3.
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